This implies that, similar to other cardiovascular and metabolic treatments, people cannot discontinue the medication if they wish to maintain their weight loss
The study population was diabetes patients with existing tobacco use disorder (TUD)
PubMed laboratory research record [PMID: 2099360] PubMed record related to this compound for laboratory literature review
This immune activation may, in turn, affect the CNS, exacerbating fatigue and cognitive symptoms
In Italy, the classes under consideration include GLP-1 receptor agonists (dulaglutide, exenatide, exenatide LAR, liraglutide, lixisenatide, semaglutide) and also GIP/GLP-1 dual agonists (tirzepatide)